For Quick Alerts
For Daily Alerts

Suven Life Sciences bags product patents for NCEs in US, Japan

By Religare

Biopharmaceutical firm, Suven Life Sciences Ltd. today said that the company has received two product patents, one from Japan and other from the US, for the New Chemical Entities (NCEs) indicated for treatment of disorders associated with Neurodegenerative diseases.

Valid through 2028 & 2029, the patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. With these 2 patents, Suven has a total of 6 granted patents from Japan and 12 from the US, the company said in a filing to the Bombay Stock Exchange.


The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders, the filing added.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally," Suven Life Sciences, CEO, Venkat Jasti said.

Read more about: suven life sciences
Story first published: Friday, June 28, 2013, 22:57 [IST]
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more